These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
166 related articles for article (PubMed ID: 1378515)
1. Progression of early steps of human immunodeficiency virus type 1 replication in the presence of an inhibitor of viral protease. Jacobsen H; Ahlborn-Laake L; Gugel R; Mous J J Virol; 1992 Aug; 66(8):5087-91. PubMed ID: 1378515 [TBL] [Abstract][Full Text] [Related]
3. Antiviral activity of human immunodeficiency virus type 1 protease inhibitors in a single cycle of infection: evidence for a role of protease in the early phase. Nagy K; Young M; Baboonian C; Merson J; Whittle P; Oroszlan S J Virol; 1994 Feb; 68(2):757-65. PubMed ID: 8289379 [TBL] [Abstract][Full Text] [Related]
4. De novo reverse transcription is a crucial event in cell-to-cell transmission of human immunodeficiency virus. Li P; Kuiper LJ; Stephenson AJ; Burrell CJ J Gen Virol; 1992 Apr; 73 ( Pt 4)():955-9. PubMed ID: 1378883 [TBL] [Abstract][Full Text] [Related]
5. Unintegrated HIV-1 circular 2-LTR proviral DNA as a marker of recently infected cells: relative effect of recombinant CD4, zidovudine, and saquinavir in vitro. Panther LA; Coombs RW; Aung SA; dela Rosa C; Gretch D; Corey L J Med Virol; 1999 Jun; 58(2):165-73. PubMed ID: 10335865 [TBL] [Abstract][Full Text] [Related]
6. Effects of zidovudine-selected human immunodeficiency virus type 1 reverse transcriptase amino acid substitutions on processive DNA synthesis and viral replication. Caliendo AM; Savara A; An D; DeVore K; Kaplan JC; D'Aquila RT J Virol; 1996 Apr; 70(4):2146-53. PubMed ID: 8642636 [TBL] [Abstract][Full Text] [Related]
7. Human immunodeficiency virus type 1 infection requires reverse transcription of nascent viral RNA. Potash MJ; Li G; Shahabuddin M; Pellegrino MG; Volsky DJ DNA Cell Biol; 1993 Oct; 12(8):685-93. PubMed ID: 7691074 [TBL] [Abstract][Full Text] [Related]
8. Mode of action of SDZ NIM 811, a nonimmunosuppressive cyclosporin A analog with activity against human immunodeficiency virus type 1 (HIV-1): interference with early and late events in HIV-1 replication. Steinkasserer A; Harrison R; Billich A; Hammerschmid F; Werner G; Wolff B; Peichl P; Palfi G; Schnitzel W; Mlynar E J Virol; 1995 Feb; 69(2):814-24. PubMed ID: 7815548 [TBL] [Abstract][Full Text] [Related]
9. Synergistic drug interactions of an HIV-1 protease inhibitor with AZT in different in vitro models of HIV-1 infection. Lambert DM; Bartus H; Fernandez AV; Bratby-Anders C; Leary JJ; Dreyer GB; Metcalf BW; Petteway SR Antiviral Res; 1993 Aug; 21(4):327-42. PubMed ID: 7692816 [TBL] [Abstract][Full Text] [Related]
10. An inhibitor of the protease blocks maturation of human and simian immunodeficiency viruses and spread of infection. Ashorn P; McQuade TJ; Thaisrivongs S; Tomasselli AG; Tarpley WG; Moss B Proc Natl Acad Sci U S A; 1990 Oct; 87(19):7472-6. PubMed ID: 2217178 [TBL] [Abstract][Full Text] [Related]
11. Inhibition of the protease of human immunodeficiency virus blocks replication and infectivity of the virus in chronically infected macrophages. Perno CF; Bergamini A; Pesce CD; Milanese G; Capozzi M; Aquaro S; Thaisrivongs S; Tarpley WG; Zon G; D'Agostini C J Infect Dis; 1993 Nov; 168(5):1148-56. PubMed ID: 8228348 [TBL] [Abstract][Full Text] [Related]
12. Inhibition of HIV by an anti-HIV protease synthetic peptide blocks an early step of viral replication. Venaud S; Yahi N; Fehrentz JL; Guettari N; Nisato D; Hirsch I; Chermann JC Res Virol; 1992; 143(5):311-9. PubMed ID: 1480823 [TBL] [Abstract][Full Text] [Related]
13. DNA found in human immunodeficiency virus type 1 particles may not be required for infectivity. Arts EJ; Mak J; Kleiman L; Wainberg MA J Gen Virol; 1994 Jul; 75 ( Pt 7)():1605-13. PubMed ID: 7517431 [TBL] [Abstract][Full Text] [Related]
14. CGP 53437, an orally bioavailable inhibitor of human immunodeficiency virus type 1 protease with potent antiviral activity. Alteri E; Bold G; Cozens R; Faessler A; Klimkait T; Lang M; Lazdins J; Poncioni B; Roesel JL; Schneider P Antimicrob Agents Chemother; 1993 Oct; 37(10):2087-92. PubMed ID: 8257128 [TBL] [Abstract][Full Text] [Related]
15. Multiple effects of mutations in human immunodeficiency virus type 1 integrase on viral replication. Engelman A; Englund G; Orenstein JM; Martin MA; Craigie R J Virol; 1995 May; 69(5):2729-36. PubMed ID: 7535863 [TBL] [Abstract][Full Text] [Related]
16. A rodent cell line permissive for entry and reverse transcription of human immunodeficiency virus type 1 has a pre-integration block to productive infection. Simon JH; Schockmel GA; Illei P; James W J Gen Virol; 1994 Oct; 75 ( Pt 10)():2615-23. PubMed ID: 7523578 [TBL] [Abstract][Full Text] [Related]
17. Polymerase substrate depletion: a novel strategy for inhibiting the replication of the human immunodeficiency virus. Ichimura H; Levy JA Virology; 1995 Aug; 211(2):554-60. PubMed ID: 7544050 [TBL] [Abstract][Full Text] [Related]
18. Inhibition of the human immunodeficiency virus-1 protease and human immunodeficiency virus-1 replication by bathocuproine disulfonic acid Cu1+. Davis DA; Branca AA; Pallenberg AJ; Marschner TM; Patt LM; Chatlynne LG; Humphrey RW; Yarchoan R; Levine RL Arch Biochem Biophys; 1995 Sep; 322(1):127-34. PubMed ID: 7574666 [TBL] [Abstract][Full Text] [Related]
19. The site of antiviral action of 3-nitrosobenzamide on the infectivity process of human immunodeficiency virus in human lymphocytes. Rice WG; Schaeffer CA; Graham L; Bu M; McDougal JS; Orloff SL; Villinger F; Young M; Oroszlan S; Fesen MR Proc Natl Acad Sci U S A; 1993 Oct; 90(20):9721-4. PubMed ID: 7692451 [TBL] [Abstract][Full Text] [Related]
20. Association of integrase, matrix, and reverse transcriptase antigens of human immunodeficiency virus type 1 with viral nucleic acids following acute infection. Bukrinsky MI; Sharova N; McDonald TL; Pushkarskaya T; Tarpley WG; Stevenson M Proc Natl Acad Sci U S A; 1993 Jul; 90(13):6125-9. PubMed ID: 7687060 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]